Paper19917871
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.
Azzoli CG and 19 others. J Clin Oncol, 2009. Cited by 619 papers, by iCite.
Cite this record
ConductScience Library. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Papers, record 19917871. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19917871
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.
- PubMed
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Humans | |
| Neoplasm Staging |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03976518 | Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) | Background |
Source ClinicalTrials.gov
References151
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18283036 | A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. | Ann Oncol | 2008 | https://conductscience.org/library/papers/18283036 | PubMed |
| 2 | 18316562 | Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group Study. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18316562 | PubMed |
| 3 | 17720276 | Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. | Lung Cancer | 2008 | https://conductscience.org/library/papers/17720276 | PubMed |
| 4 | 15741570 | Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. | J Natl Cancer Inst | 2005 | https://conductscience.org/library/papers/15741570 | PubMed |
| 5 | 15728228 | Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15728228 | PubMed |
| 6 | 18809811 | Missed opportunities for interval empathy in lung cancer communication. | Arch Intern Med | 2008 | https://conductscience.org/library/papers/18809811 | PubMed |
| 7 | 17047648 | A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. | Br J Cancer | 2006 | https://conductscience.org/library/papers/17047648 | PubMed |
| 8 | 16014882 | Erlotinib in previously treated non-small-cell lung cancer. | N Engl J Med | 2005 | https://conductscience.org/library/papers/16014882 | PubMed |
| 9 | 18375902 | Physician-identified factors affecting patient participation in reaching treatment decisions. | J Clin Oncol | 2008 | https://conductscience.org/library/papers/18375902 | PubMed |
| 10 | 19692680 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19692680 | PubMed |
| 11 | 15447984 | Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/15447984 | PubMed |
| 12 | 17602080 | Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17602080 | PubMed |
| 13 | 17762336 | The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. | J Thorac Oncol | 2007 | https://conductscience.org/library/papers/17762336 | PubMed |
| 14 | 14698542 | Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. | Lung Cancer | 2004 | https://conductscience.org/library/papers/14698542 | PubMed |
| 15 | 16467097 | Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. | Clin Cancer Res | 2006 | https://conductscience.org/library/papers/16467097 | PubMed |
| 16 | 17387341 | Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. | Br J Cancer | 2007 | https://conductscience.org/library/papers/17387341 | PubMed |
| 17 | 17346847 | Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospective observational study in advanced non-small cell lung cancer. | Lung Cancer | 2007 | https://conductscience.org/library/papers/17346847 | PubMed |
| 18 | 15205198 | Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. | Ann Oncol | 2004 | https://conductscience.org/library/papers/15205198 | PubMed |
| 19 | 16290256 | Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. | Lung Cancer | 2006 | https://conductscience.org/library/papers/16290256 | PubMed |
| 20 | 17167137 | Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. | N Engl J Med | 2006 | https://conductscience.org/library/papers/17167137 | PubMed |
Cited by247
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 619 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42876810 | Monoclonal antibodies associated IgA nephropathy or other nephropathies. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42876810 | PubMed |
| 42812841 | Optimal, Interpretable, and Personalized Immune Checkpoint Inhibitor Duration in Non-Small Cell Lung Cancer: A Multicenter Real-World Study. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42812841 | PubMed |
| 42638942 | Cost-Effectiveness Analysis of Ivonescimab Plus Chemotherapy versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer in China Based on the HARMONi-6 Trial. | Risk Manag Healthc Policy | 2026 | https://conductscience.org/library/papers/42638942 | PubMed |
| 41635837 | Case report: Immune checkpoint inhibitor-induced fulminant diabetic ketoacidosis: a case-based review and considerations for immunotherapy discontinuation. | Front Immunol | 2025 | https://conductscience.org/library/papers/41635837 | PubMed |
| 41008962 | Gas Plasma Combination Therapies-Promises from Preclinical Oncology Research. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/41008962 | PubMed |
| 39791613 | Comparing Quality of Life and Psychological Changes in Benign and Malignant Lung Resections. | Healthcare (Basel) | 2024 | https://conductscience.org/library/papers/39791613 | PubMed |
| 39717667 | Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC. | JTO Clin Res Rep | 2025 | https://conductscience.org/library/papers/39717667 | PubMed |
| 39461775 | Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial. | ESMO Open | 2024 | https://conductscience.org/library/papers/39461775 | PubMed |
| 39233826 | Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report. | Oncol Lett | 2024 | https://conductscience.org/library/papers/39233826 | PubMed |
| 39109434 | Anti-proliferation evaluation of new derivatives of indole-6-carboxylate ester as receptor tyrosine kinase inhibitors. | Future Med Chem | 2024 | https://conductscience.org/library/papers/39109434 | PubMed |
| 38880928 | [Afatinib Treatment for Advanced Mixed Non-small Cell Lung Cancer with CRISPLD2-NRG1 Fusion: A Case Report and Literature Review]. | Zhongguo Fei Ai Za Zhi | 2024 | https://conductscience.org/library/papers/38880928 | PubMed |
| 38505696 | The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases. | Int J Clin Pract | 2024 | https://conductscience.org/library/papers/38505696 | PubMed |
| 37513950 | Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides as Potential Multi-Target Antiproliferative Agents. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37513950 | PubMed |
| 37462807 | Role of GSDM family members in airway epithelial cells of lung diseases: a systematic and comprehensive transcriptomic analysis. | Cell Biol Toxicol | 2023 | https://conductscience.org/library/papers/37462807 | PubMed |
| 37031207 | PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration. | Cell Death Dis | 2023 | https://conductscience.org/library/papers/37031207 | PubMed |
| 35813717 | EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors. | J Thorac Dis | 2022 | https://conductscience.org/library/papers/35813717 | PubMed |
| 35734411 | Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35734411 | PubMed |
| 35681639 | Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35681639 | PubMed |
| 35619899 | Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies. | Front Oncol | 2022 | https://conductscience.org/library/papers/35619899 | PubMed |
| 35329953 | Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. | J Clin Med | 2022 | https://conductscience.org/library/papers/35329953 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19917871
GET https://conductscience.org/api/papers/v1/19917871/references?page=2